Lurbinectedin is a chemotherapy drug that is used to treat relapsed small cell lung cancer (SCLC). It works by interfering with DNA repair processes, which ultimately leads to cancer cell death [1]. Immunotherapy, on the other hand, is a type of cancer treatment that uses the body's immune system to fight cancer cells. It works by stimulating the immune system to recognize and attack cancer cells [2].

There is limited information available on the potential side effects of combining lurbinectedin and immunotherapy. However, a recent study published in the Journal of Thoracic Oncology reported promising preliminary activity of combining lurbinectedin and pembrolizumab in relapsed SCLC [2]. The study found that the combination therapy was well-tolerated and had a manageable safety profile. The most common adverse events reported were fatigue, nausea, and decreased appetite.

Another study published in the journal Cancers reported on the potential synergistic effects of combining lurbinectedin and immunotherapy in the treatment of solid tumors [3]. The study found that the combination therapy had the potential to enhance the anti-tumor immune response and improve treatment outcomes. However, the study also noted that the combination therapy may increase the risk of immune-related adverse events, such as autoimmune disorders and inflammation.

In conclusion, there is limited information available on the potential side effects of combining lurbinectedin and immunotherapy. However, preliminary studies suggest that the combination therapy is well-tolerated and has a manageable safety profile. Further research is needed to fully understand the potential benefits and risks of combining these two treatments [2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancernetwork.com/view/antonio-calles-md-highlights-promising-preliminary-activity-of-lurbinectedin-and-pembrolizumab-in-relapsed-sclc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/